|
Maximizing Benefit, Minimizing Risk: Managing Immune Checkpoint Inhibitor Toxicities |
1.25 |
06/15/2026 - 12:00am to 03/01/2027 - 11:59pm |
|
Recorded Presentation of NCCN Optimizing Patient Outcomes - Recent Advancements in Chemoradiation Strategies for Locally Advanced Cervical Cancer |
1.00 |
06/18/2026 - 12:00am to 06/11/2027 - 11:59pm |
|
Recorded Presentation of NCCN Optimizing Patient Outcomes - From Mutation to Treatment: Understanding the Impact of New Targeted Therapies in Central... |
1.00 |
06/26/2026 - 12:00am to 06/23/2027 - 11:59pm |
|
NCCN Tumor Boards: Induction Therapy for Ph+ B-Cell Acute Lymphoblastic Leukemia |
1.00 |
07/08/2026 - 12:00am to 12/27/2026 - 11:59pm |
|
NCCN Optimizing Patient Outcomes - Management of Bispecific T-Cell Engager Toxicities: How to Balance Increased Efficacy with Notable Toxicity |
1.00 |
07/08/2026 - 12:00am to 01/04/2027 - 11:59pm |
|
NCCN Guidelines® Insights - Myeloproliferative Neoplasms, Version 2.2026 |
1.00 |
07/10/2026 - 12:00am to 07/10/2027 - 11:59pm |
|
Recorded Presentation of NCCN Optimizing Patient Outcomes - Hitting the Right Target: Updates in Biomarker-Directed Therapy for Non-Small Cell Lung... |
1.00 |
07/22/2026 - 12:00am to 07/16/2027 - 11:59pm |
|
Archived NCCN Tumor Boards: New and Emerging Treatment Options for Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer |
1.00 |
08/05/2026 - 12:00am to 07/27/2027 - 11:00pm |
|
NCCN Tumor Boards: Management of Early-Stage, Invasive, Non-Metastatic Breast Cancer |
1.00 |
08/07/2026 - 12:00am to 01/17/2027 - 11:59pm |
Facebook
X
LinkedIn
Forward